Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro‐resected patient

Summary What is known and objective The second‐generation direct‐acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro‐resected patients. Case description We report on a ga...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacy and therapeutics 2017-10, Vol.42 (5), p.621-623
Main Authors: Taibi, C., Tempestilli, M., D'Avolio, A., Garbuglia, A. R., De Nicolò, A., Montalbano, M., D'Offizi, G.
Format: Article
Language:English
Subjects:
Aged
Antiviral agents
Antiviral Agents - administration & dosage
Antiviral Agents - pharmacokinetics
Antiviral drugs
Benzimidazoles - therapeutic use
Bioavailability
Blood levels
Chronic infection
Drug Combinations
Female
Fluorenes - therapeutic use
Gastrectomy
Hepatitis
Hepatitis C
hepatitis C virus
Hepatitis C, Chronic - drug therapy
Humans
Interferon
ledipasvir
Liver
Patients
pharmacokinetics
sofosbuvir
Time Factors
Treatment Outcome
Uridine Monophosphate - analogs & derivatives
Uridine Monophosphate - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary What is known and objective The second‐generation direct‐acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro‐resected patients. Case description We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability. We describe the first reported case of treatment with direct antiviral agents in a gastrotomized patient. This report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating Sofosbuvir/Ledipasvir bioavailability.
ISSN:0269-4727
1365-2710
DOI:10.1111/jcpt.12546